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ABSTRACT
Reciprocal interactions between cancers and the surrounding microenvironment 
have an important role in tumour evolution. In this study, our data suggested that 
through thrombospondin 1 (TSP1), tumour-associated microvessel provides a 
dormant niche to sustain inactive status of breast invasive ductal carcinoma (IDC) 
cells. TSP1 levels in the tumour stroma were negatively correlated with vascular 
indoleamine 2,3-dioxygenase 1 (IDO1) in IDC tissues. IDO1 is an intracellular 
enzyme initiating the first and rate-limited step of tryptophan breakdown. Lower 
stromal TSP1 levels and positive tumour vascular IDO1 staining seems to associate 
with poor survive of patients with IDC. IDC cells induced a significantly increase 
in IDO1 expression in endothelial cells (ECs). IFNγ exerts a similar effect on ECs. 
We hypothesized a tryptophan starvation theory that since tryptophan is essential 
for the synthesis of TSP1, IDO1 induce a decrease in tryptophan availability and a 
reduction in TSP1 synthesis in ECs, leading to overcoming the dormancy state of IDC 
cells and exacerbating conditions such as tumour invasion and metastasis. These 
findings identify a non-canonical role of IFNγ/IDO1/TSP1 axis in microvascular niche-
dominated dormancy of breast invasive ductal carcinoma with a solid foundation for 
further investigation of therapeutic and prognostic relevance.
INTRODUCTION
Invasive ductal carcinoma (IDC) is an aggressive 
form of breast cancer and the most common cancer in 
women worldwide [1]. Despite numerous advances in 
diagnosis and treatment, invasion and metastasis remain 
the primary cause of death associated with IDC. 10% to 
30% of patients with IDC diagnosed at an early stage 
with no evidence of metastatic lymph node manifest 
with metastasis after >10 years of the first diagnosis. 
Within tumour microenvironment, interactions between 
tumour cells and stromal cells (such as tumour vascular 
endothelial cells) determine the extent of tumour growth 
[2]. While most tumour cells are detected and eliminated 
by host defence system, some stay in a dormant state 
where an equilibrium with the host system is reached-
tumour dormancy [3, 4]. IDC recurrence probably is 
mainly due to tumour dormancy rather than the re-growth 
of the residual cancers in patients [5, 6, 7].
Prolonging tumour dormancy has been proposed 
as a promising approach to inhibit tumour growth and 
metastasis [8]. However, tumour dormancy is difficult 
to study, especially in clinical settings. In a metastatic 
mouse model, dormant IDC cells were observed near 
the lung, brain and bone marrow microvasculature [9]. 
Stable microvascular niche can sustain the quiescence 
of IDC cells. Thrombospondin 1 (TSP1), a large matrix 
glycoprotein, is the most abundant potent endogenous 
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inhibitory component in the stable microvascular niche 
via mediating cell-to-cell and cell-to-matrix interactions. 
Lower levels of TSP1 expression frequently observed at 
the advance front of invasive breast cancer are significantly 
correlated with metastasis in tumour progression [10]. 
Vascular endothelial cells (ECs) are responsible for the 
majority of TSP1 secreted into the tumour stroma [11].
Indoleamine 2,3-dioxygenase 1 (IDO1) overexpresses 
in variety types of tumours including breast cancer 
[12, 13]. The pathologic significance of IDO1 in breast 
cancer involves in a complex of regulatory interactions of 
metabolism and immune. IDO1 is an intracellular immune 
checkpoint enzyme that catalyses tryptophan during the 
first and rate-limited step of L-tryptophan degradation, 
exerts a crucial immune tolerance role in inflammation 
response. There are conflicting results regarding the 
correlation of the high levels of IDO1 expression with 
lymph node involvement of breast cancer. However, the 
increased IDO1 in tumour endothelial cells was associated 
with limitation of the tryptophan influx from the blood 
circulation [14].
Interferon-γ (IFNγ) has been shown to induce 
IDO1 in a variety of malignancies [15]. A detailed study 
revealed that local IFNγ could directly target tumour 
vascular endothelial cells and affect tumour stroma [16]. 
IFNγ is a cytokine whose biological activity associated 
with modulating innate and adaptive immune responses 
[17]. There are conflict results regarding the role of IFNγ 
in tumour progression. Early in vivo study showed that 
neutralising IFNγ enhanced tumour growth, suggesting 
that IFNγ protects malignant lesions [18]. Consistently, 
the overexpression of dominant negative IFNγ receptors 
caused a significant increase in tumour growth in vivo 
models [19]. Surprisingly, there are reports that IFNγ 
protecting cells from inflammation insults might allow 
malignant cells to evade elimination, manifesting pro-
tumorigenic activities [20]. For instance, intratumoral 
expression of IFNγ strengthened the aggressiveness of 
melanoma including lung colonization [21].
Since IDC represent one of the least immunogenic 
tumours, we hypothesized that IDC cells initiate a negative 
feedback loop in TSP1-dependent tumour growth arrest. 
Firstly, high levels of TSP1 in stroma suppressed the IDC 
cells directly. The antitumor effects result in recognition 
and elimination of the stromal TSP1 by the IDC cells, 
triggering an increase in IFNγ-stimulated IDO1 levels in 
the adjacent vascular ECs. Secondly, the vascular IDO1 
serves as the major negative regulator of the stromal 
TSP1 proteins by degrading tryptophan. Thirdly, since 
sequencing analysis reveals that TSP1 contains a higher 
percentage of mannosylated L-tryptophan in the type 1 
repeats [22], the resultant tryptophan deprivation leads to 
a reduction in IDC-associated vascular ECs synthesizing 
TSP1. Finally, a reduction in the stromal TSP1 proteins 
ultimately leads to the escape of the IDC cells from the 
siege of stromal TSP1. This study provided evidence that 
different signal regulation of crosstalk within tumour 
microenvironment might be a critical event in tumour 
dormancy regarding IDC development and metastasis. To 
this end, our observations not only confirm the notion of 
targeting IDO1 for breast cancer treatment but may raise 
potential concerns regarding the efficacy and safety of 
IFNγ for broadly clinical usage.
RESULTS
Endothelial cells exerts an inhibitory effect on IDC 
cells, leading to the cell cycle arrest of IDC cells
Ghajar et al. 2013 showed that mutual interaction 
between breast tumour and endothelial cells within the 
tumour microenvironment might directly regulate the 
dormant disseminated tumour cells [9]. They demonstrated 
that endothelial cells-dominated vascular niche is a critical 
component in the dormancy of these cells. We developed an 
in vitro co-culture system and investigated the influence of 
ECs on the behaviours of breast tumour cells (described in 
MATERIALS and METHODS) (Figure 1A). Interestingly, 
the proliferation of a non-tumorigenic breast cell line (MCF-
10A) was not affected by ECs and accounted for almost 
80% of the total cell number after 48 hours (Figure 1B). In 
contrast, a substantial decrease in the percentage of breast 
tumour cancer cells was detected in both MCF-7 and MDA-
MB-231 (13.1% and 30.6% respectively) (Figure 1B). We 
examined the effects of ECs in the induction of dormancy 
in IDC cells through flow cytometric analysis of the cell 
cycle of the MDA-MB-231, MDA-MB-436 and MCF-
10A. Notably, the both MDA-MB-231 and MDA-MB-436 
cells co-cultured with ECs had a high percentage of cells in 
the G0/G1 phase and a significantly low level in the G2/M 
phase in compared with control (single culture group), 
whereas MCF-10A did not exhibit a difference between 
co-culture and single culture (Figure 1C). Interestingly, 
ECs did not induce a detectable change in S phase. We 
further investigated whether ECs regulate proliferation 
of IDC cells by measuring a proliferation marker Ki67 
using flow cytometry. Our data indicate that the interaction 
with ECs led to a significantly decrease in Ki67 positive 
MDA-MB-231 cells (Figure 1D). MDA-MB-231 cells 
are less active when co-cultured with ECs (Ki67+ MDA-
MB-231 cells: 72.80%) than the single culture of MDA-
MB-231 (Ki67+ MDA-MB-231 cells: 97.49%). However, 
flow cytometric analysis did not show any difference in 
senescence marker p21 expression in MDA-MB-231 
cells between single culture or co-culture with ECs 
(Supplementary Material and Supplementary Figure 1A).
EC-derived TSP1 suppresses proliferation of 
IDC cells
In a recapitulation of the findings from in vitro 
co-culture of IDC cells with ECs, we co-cultured MDA-
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MB-231 cells with conditioned medium from ECs. As 
shown in Figure 2A, flow cytometric analysis revealed 
that the treatment of conditioned medium from ECs for 48 
hours induced a significant reduction in the proliferation 
of MDA-MB-231 cells (Ki67+MDA-MB-231 cells: 
70.25%) compared to the normal medium group (Ki67+ 
MDA-MB-231 cells: 88.29%). We speculated that 
vascular ECs within tumour microenvironment might 
Figure 1: Co-culture of breast tumour cells with endothelial cells. (A) Fluorescence microscope representative pictures of 2D 
co-culture in vitro model composed with different breast tumour cells and endothelial cells (ECs) in a 1:1 ratio. (B) Quantification of the 
ratio of the cells in co-culture after 48 hours by flow cytometry (1,000,000 cells of each cell type were initially seeded in each well). (C) 
Percentage of MDA-MB-231, MDA-MB-436 and MCF-10A cells in G0/G1, S and G2/M phase 48 hours after single culture or in co-
culture with human dermal microvascular EC (HMEVCa-D) cells. (D) Sorting plots and gates were used for Ki67 analysis. The plot in red 
showed the percentage of Ki67 positive cells when MDA-MB-231 cells were cultured alone. The plot blue showed the percentage of Ki67 
positive cells when MDA-MB-231 cells were co-cultured with HMEVCa-D for 48 hours.
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suppress the proliferation of breast cancer cells via the 
secreted molecules, such as TSP1. We also analysed three 
standard endothelial cell (EC) lines for the expression of 
TSP1 proteins, including human dermal microvascular 
endothelial cells (HMVECa-D), human vascular umbilical 
cord ECs (HUVECs) and a cerebral microvascular ECs 
(CMECs). ELISA failed to detect any levels of TSP1 from 
the EC medium (data not shown). ELISA analysis showed 
detectable TSP1 proteins ranged from 100 to 50 ng/ml 
from the EC-conditioned medium from the all three tested 
ECs (Figure 2B). To determine whether EC-derived TSP1 
suppresses IDC cell viability, we treated MDA-MB-231 
cells with recombinant human TSP1 proteins at different 
concentrations (0, 10, 50 and 100 ng/ml) for 48 hours. TSP1 
treatment did exert a significantly inhibitory effect on the 
viability of MDA-MB-231 cells at dose-dependent manner 
(Figure 2C). Flow cytometric analysis of Ki67 expression 
confirmed that TSP treatment (100 ng/ml) significantly 
Figure 2: TSP1 reduces proliferation of IDC cells. (A) Comparison of the percentage of Ki67 positive MDA-MB-231 cells cultured 
with the HMEVCa-D cell-conditioned medium with the normal control groups. (B) ELISA analysis of TSP1 expression levels in the 
supernatants obtained from a panel of vascular endothelial cells. (C) Cell viability assay showing that recombinant TSP1 proteins inhibit 
proliferation of MDA-MB-231 cells with the greatest effect at 100ng/ml. (D) Decreased percentage of Ki67 positive MDA-MB-231 cells 
after treated with 100ng/ml of TSP1 for 24 hours.
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reduced Ki67+ MDA-MB-231 cells compared with control 
group (78.13%±3.250 vs. 87.56%±0.2881; 95%CI -18.48 
to -0.3843; R2=0.6768; p=0.0444) (Figure 2D). Since TSP1 
suppressed the proliferation of MDA-MB-231 cells, it was 
logic for us to assess whether TSP1 treatment also induces 
apoptosis of MDA-MB-231 cells. Surprisingly, TSP1 
treatment (100 ng/ml) did not cause a detectable apoptotic 
effect on MDA-MB-231 cells compared to the control 
group (Supplementary Figure 1B).
Differential expressions of TSP1 in IDC tissues 
with its stromal expression inversely are related 
to IDC progression
We performed semi-quantitative immunohistochemical 
(IHC) analysis of the expressions of TSP1 in commercial 
tissue microarrays of 100 human breast cancer specimens 
or adjacent normal tissues, scoring expression from 0 
(no expression) to 3 (high expression). We observed that 
TSP1 immunostaining was very weak in invasive breast 
carcinoma and an increase in TSP1 staining in adjacent 
normal tissues (Figure 3A, 3B). Interestingly, there was 
an increase in TSP1 expression in metastasis to lymph 
nodes. TSP1 was observed as typical fine fibrillary 
stromal staining as well as in the basement membrane of 
duct space (Figure 3B). TSP1 expression was higher in 
adjacent normal tissue than in invasive breast carcinoma 
(staining intensities, SI: 1.100±0.100 vs. 0.5200±0.08685, 
p<0.0001, Table 1), but higher in metastatic lymph node 
than in adjacent normal tissues (SI: 1.226±0.1006 vs. 
1.100±0.100, p<0.0001, Table 1).
To further measure the positive staining area of the 
commercial tissue microarrays of 100 human breast cancer 
specimens or adjacent normal tissues, we performed the 
histomorphometry analysis by adapting an eyepiece 
systematic point-sampling technique (described in 
MATERIALS and METHODS) (Figure 3E). TSP1 staining 
occupied the most of the stroma (Figure 4A). Stromal 
TSP1 was seen 40 out of 50 primary IDC cases (Table 2). 
As shown in Figure 4C, ANOVA analysis showed that 
there was a significant and inverse correlation between 
the degree of tumour stromal TSP1 and the TNM grading 
(R2=0.1823; p<0.05), even though mean TSP1 values in 
the T2 seemed to increase compared to T1 group. The 
T1 group (n=6) represent patients with tumour invading 
submucosa (mean TSP1: 9.90%). The T2 (n=27) contains 
patients with tumour invading muscularis propria (mean 
TSP1: 12.31%). The T3 patients (n=9) had tumours 
invading through muscularis propria into subserosa or non-
peritonealized pericolic or perirectal tissues (mean TSP1: 
2.089%), whereas T4 group (n=10) containing tumour 
directly invades other organs or structures and/or perforate 
visceral peritoneum (mean TSP1: 1.900%). Another tool 
for the evaluation of tumour prognosis is to evaluate 
the differentiation of the tumour cells (Supplementary 
Materials). A higher grade usually corresponds to a more 
aggressive cancer (Figure 4E). There is an even more 
apparent difference (R2=0.1480; p<0.05) in the degree 
of tumour stromal TSP1 between the well differentiated 
Grade 1 tumours (mean TSP1: 17.43%; n=6), than the 
modestly differentiated Grade 2 classed tumours (mean 
TSP1: 5.738%; n=32), and the poorly differentiated Grade 
3 tumours (mean TSP1: 4.333%; n=6).
Stromal TSP1 expression is inversely related to 
vascular IDO1 expression in primary IDC tissues
Recent studies suggested that IFNγ can induce an 
overexpression of IDO1 in varieties types of tumours 
including breast cancer, followed by a breakdown of 
tryptophan [23]. We also performed IHC staining of IDO1 
in the same commercial tissue microarrays as described 
previous (Figure 3C, 3D). In contrast to TSP1 expression, 
adjacent normal tissues expressed relatively small amounts 
of IDO1 (SI of 0.60±0.2667), compared to IDC (SI of 
1.560±0.09545, p<0.001) (Figure 3D and Table 1). Again, 
the IDO1 expression pattern in metastatic lymph nodes 
was different, with the intensity of IDO1 staining in lymph 
node metastasis lower than in primary IDC, with average 
SI of 1.375±0.08539 (p<0.001).
We found that none of IDC tissues were entirely 
negative for IDO1 staining, many of them also were in 
Table 1: Summary of IHC intensity results
Staining intensity (SI) Average ±SEM
0 1 2 3
Adjacent normal (n=10) TSP1 0 9 1 0 1.100±0.100
IDO1 7 2 1 0 0.6000±0.2667
Invasive ductal carcinoma (n=50) TSP1 26 23 0 1 0.5200±0.08685***
IDO1 0 23 23 4 1.560±0.09545***
Lymph node metastasis (n=40) TSP1 9 26 3 2 1.226±0.1006***
IDO1 0 26 13 1 1.375±0.08539***
Statistical significance was determined by One-way ANOVA. ***P<0.0001
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stromal fraction (Figure 4B). However, vascular IDO1 
staining was present in most of primary IDC cases (49/50) 
(Table 2). Unfortunately, no significant association is 
found between the vascular IDO1 and TNM grading 
(R2=0.04933; p>0.05) (Figure 4D). Interestingly, the 
vascular IDO1 expression is significantly correlated with 
the differentiation grade of IDC. As shown in Figure 
4F, the differentiated degree of primary invasive well-
differentiated Grade I tumours contain 2.633% of vascular 
IDO1, which is reduced to 0.9438% of vascular IDO1 in 
the modestly differentiated Grade 2 and disappeared at the 
poorly differentiated Grade 3.
Figure 3: TMA of human invasive ductal carcinoma patients. (A) Photograph of IDC patient tissue microarry immun-
ohistochemically stained for TSP1. (B) Representative immunostaining of TSP1 in a tumour TMA compiled from adjacent normal tissue, 
lymph node metastasis and primary invasive ductal carcinoma. (C) Photograph of IDC patient tissue microarray immunohistochemically 
stained for IDO1. (D) Representative immunostaining of IDO1 in a tumour TMA compiled from adjacent normal tissue, lymph node 
metastasis and primary invasive ductal carcinoma. (E) An eyepiece systemic point-sampling grid with 100 points and 50 lines to count the 
number of points overlying positively-stained structures at 400× magnification for histomorphometric analysis. 
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Since TSP1 contain a high percentage of tryptophan, 
[22] we speculated that the vascular IDO1 acts as a critical 
negative regulator of the tumour suppressive activity of 
stromal TSP1 in human breast cancer. A good correlation 
of IHC staining between the stromal TSP1 and vascular 
IDO1 was observed in primary IDC tissues. An increase 
in the vascular IDO1 was significantly associated with a 
decrease in the stromal TSP1 in IDC tissues (Figure 4G), 
Figure 4: Histomorphometric analysis of TSP1 and IDO1 in a TMA of human invasive ductal carcinoma patients. 
(A) Plot of percentage of immunostaining TSP1 covering different areas on tissue microarray, including adjacent normal tissues, invasive 
ductal carcinoma and lymph node metastasis. (B) Plot of percentage of immunostaining IDO1 covering different areas on tissue microarray, 
including adjacent normal tissues, invasive ductal carcinoma and lymph node metastasis. (C) A significantly association between decreased 
histomorphometric scores of the stromal TSP1 and high TNM status (p=0.0207). (D) A trend toward reduced histomorphometric scores of 
the vascular IDO1 was observed in patients with IDC who had an overall poor outlook (T3 and T4), compared with those patients with a 
relative good prognosis (T1 and T2). (E) Decreased histomorphometric scores of the stromal TSP1 was significantly correlated with poor 
differentiated grade tumours (p=0.0375). (F) Histomorphometric scores of the vascular IDO1 significantly decreased in IDC tissues with 
poor differentiated grade with the observation that the lower vascular IDO1 were in high TNM status (p=0.0247). (G) Plot of the vascular 
IDO1 (histomorphometric scores as % of points) on the horizontal axis versus the stromal TSP1 (histomorphometric scores as % of points) 
on the vertical axis. The trend in the points is given by the line with as statistical significance (R2=0.1125, p=0.0456).
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suggesting that low stromal TSP1 and high vascular IDO1 
expressions at the primary site may be considered as 
markers for the evolution of the cancerous breast lesions.
Furthermore, overall survival was compared 
(between low vs. medium/high groups) for both 
histomorphometric scores of the stromal TSP1 and the 
vascular IDO1. Unfortunately, there was no statistically 
significant difference between the stromal TSP1-low and 
stromal TSP1-medium/high groups (HR: 1.781 vs. 0.5613; 
95%CI: 0.5192 to 6.113 vs. 0.1636 to 1.926; p=0.3587) 
(Supplemental Figure 2A). However, total survival trended 
toward superiority in the stromal TSP1-medium/high 
group. For the vascular IDO1, there was no statistically 
significant different between the low and medium/high 
group (HR: 0.8514 vs. 1.188; 95% CI: 0.2675 to 2.647 
vs. 0.3778 to 3.738; p=0.8714). Interestingly, the total 
survival curve also exhibited a trend of superiority for the 
vascular IDO1-low group compared to the vascular IDO1-
medium/high group (Supplementary Figure 2B).
IDC cell-derived IFNγ abolishes the inhibitory 
effect of stromal TSP1 on the IDC cells
IFNγ is predominately produced by several immune 
cells as part of the innate immune response. However, a 
previous study revealed that different immunoreaction to 
IFNγ in three breast lesions (benign, in situ and infiltrating 
breast cancers) with the highest level in the in situ lesion 
[16]. Thus, we speculate that breast cancer cells might 
also express IFNγ. We detected that MDA-MB-231 
(tumorigenic metastatic breast cancer line) expressed 
a higher mRNA level of IFNγ than MCF-10A (non-
tumorigenic breast tumour cell line) (Figure 5A). We also 
examined whether low glucose medium (LGM) could 
further increase IFNγ expression in IDC cells. Indeed, we 
found that low glucose medium (1 mM glucose) caused 
an almost 100-fold increase in IFNγ expression in MDA-
MB-231 cells, which was completely abolished by the co-
cultured with ECs (Figure 5A). Meantime, we observed 
that ECs significantly increased IDO1 expression in 
the presence of MDA-MB-231 cells or 10 ng/ml IFNγ, 
while ECs seems not to affect IDO1 expression in MDA-
MB-231. (Figure 5B). Western blot data further confirmed 
that IFNγ induced an increase in IDO1 expression in the 
ECs at dose-dependent manner (Figure 5C).
Recently, Ghaiar et al. attributed the breast 
tumour dormancy to high concentrations of TSP1 in a 
microenvironment, which enabled breast cancer cell 
to remain quiescent [9]. We assessed whether there is a 
change in TSP1 levels of ECs upon treatment of different 
concentrations IFNγ. Indeed, ELISA analysis revealed 
that IFNγ treatment caused a dose-dependent inhibition of 
TSP1 expression in ECs (IC50 ≈10 ng/ml of IFNγ) (Figure 
6A). Since TSP1 contains a high percentage of tryptophan, 
we determined whether the availability of extracellular 
tryptophan could affect the TSP1 synthesis in ECs. We 
loaded ECs with the medium implemented with different 
concentrations of tryptophan. Our ELISA data showed 
that addition of tryptophan for 72 hours resulted in a dose-
dependent increase in TSP1 expression in ECs (IE50 ≈5μM 
of tryptophan) (Figure 6B and Supplementary Figure 3A).
IFNγ-induced vascular IDO1 deprives the 
availability of tryptophan for TSP1 synthesis by 
ECs
Addition to the immunomodulatory effects of IDO1 
on tumour cells, we speculated that IDC cells (via IFNγ) 
-induced IDO1 in ECs could catalyse the oxidation of 
L-tryptophan into kynurenine, which results in a reduction 
in the availability of tryptophan for the TSP1 synthesis by 
ECs. Accordingly, we measured the L-kynurenine levels 
of ECs as a way to assess IDO1 enzymatic activity. We, 
indeed, observed a marked increase in the extracellular 
L-kynurenine of ECs treated with the conditioned 
medium from MAD-MB-231 cells (normal glucose 
and low glucose), indicating a significant increase in 
tryptophan degradation (Figure 6C). Apart from IDO1, 
there are two other enzymes responsible for catalysing 
tryptophan including tryptophan 2,3-dioxygenase 
(TDO) and IDO2. We used a commercial IDO1 siRNA 
to successfully knockdown IDO1 expression up to 
Table 2: Summary of IHC morphometric results
Mean minimum maximum
Tumour Cells (%)
TSP1 2.12 0.00 16.50
IDO1 43.068 5.00 98.60
Stromal (%)
TSP1 6.576 0.00 42.20
IDO1 44.012 0.00 76.60
Vasculature (%)
TSP1 0.016 0.00 0.08
IDO1 1.112 0.00 4.60
The units “% of points” indicate the number of points overlying the structure of interest divide by total number of points 
overlying the tissues.
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~90% in ECs pretreated with the conditioned medium of 
MDA-MB-231 (Supplementary Figure 3B), while TDO 
and IDO2 mRNA were not affected (Supplementary 
Figure 3C). Interestingly, the conditioned medium from 
MDA-MB-231 cells did not increase either TDO or IDO2 
expression in ECs, and our IDO1 siRNA treatment did 
not lead to the detectable upregulation of both enzymes 
(Data no shown). To further confirm IDO1-catalysed 
tryptophan as the primary reason for the TSP1 reduction, 
we measured L-kynurenine levels of ECs upon IDO1 
siRNA treatment. IDO1 siRNA treatment significantly 
reduced the L-kynurenine levels of ECs treated with either 
Figure 5: Breast tumour cancer cells express IFNγ inducing an increase in IDO1 expression in ECs. (A) IFNγ mRNA 
expression is significantly up-regulated in MDA-MB-231 than those in MCF-10A (normal breast epithelial cells), which is further enhanced 
by low glucose (LGM) exposure for 48 hours compared with normal glucose (NM) medium. Also, IFNγ expression in MDA-MB-231 is 
reduced after co-cultured with endothelial cells for 48 hours. (B) Differential IDO1 mRNA expression in MDA-MB-231 and ECs occurs 
after single culture or co-culture for 48 hours. IDO1 mRNA levels significantly increase in endothelial cells after treated with IFNγ for 48 
hours. (C) Western blot analysis confirms that IFNγ treatment induces an increase in IDO1 protein levels in endothelial cells using anti-
IDO1 antibody (the upper panel), analysed by measuring band density (the low panel). GAPDH was used as an internal control.
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co-cultured with the conditioned medium or LGM of 
MDA-MB-231 (Figure 6C). Furthermore, 1-methyl-[D]-
tryptophan (1-MT), an IDO1 inhibitor, caused a remarked 
reduction in L-kynurenine levels of ECs (Figure 6C). Our 
data provide clear evidence that the elevated endothelial 
IDO1 caused a decrease in intracellular tryptophan levels. 
These experiments provide initial evidence that IDC cells, 
in part via IFNγ, induce endogenous IDO1 expression 
by ECs serves as an evasive mechanism against TSP1 of 
tumour dormancy (Figure 6D).
Figure 6: Functional importance of IFNγ/IDO1/TSP1 axis. (A) ELISA assay shows that IFNγ induces a reduction in HMEVCa-D 
cells secreting TSP1 into extracellular space with IC50=10ng/ml. (B) HMEVCa-D cells were treated with the medium implemented with 
different concentrations of tryptophan. Addition of tryptophan for 72 hours resulted in an increase in TSP1 expression in ECs with IE50 
of approximately 5μM. (C) ELISA assay reveals that the MDA-MB-231 cell-conditioned medium (normal or low glucose) induced a 
significantly increase in intracellular L-kynurenine protein levels in HMEVCa-D cells, an indication of tryptophan degradation, which is 
reversed by IDO1 siRNA and IDO1 inhibitor-1-Methyl-tryptophan (1MT). (D) A possible non-canonical role of IFNγ/IDO1/TSP1 axis in 
microvascular niche-dominated tumour dormancy of breast invasive ductal carcinoma cells. High levels of TSP1 in stroma suppressed the 
IDC cells directly. The antitumor effects result in recognition and elimination of the stromal TSP1 by the IDC cells, triggering an increase 
in IFNγ-stimulated IDO1 levels in the adjacent vascular ECs. The vascular IDO1 serves as the major negative regulator of the stromal TSP1 
proteins by degrading tryptophan, one essential amino acid for TSP1 synthesis, which ultimately leads to a reduction in the stromal TSP1 
proteins and the escape of the IDC cells from siege of stromal TSP1.
Oncotarget11www.impactjournals.com/oncotarget
DISCUSSION
TSP1 is a large matricellular glycoprotein in 
tumour stroma. Like other matricellular proteins, TSP1 
exerts a multiple functions, even sometimes opposite, 
on tumour progression depending on the molecular 
nature of malignant lesions [24, 25]. Many non-platelet 
sources have been identified to produce TSP1 within the 
tumour microenvironment, such as endothelial cells [26]. 
cancer cells (adhesive or circulating) [27]. Ghajar et al. 
demonstrated that the quiescent breast tumour cells often 
enter into a long-term dormancy [9]. The fact that the 
dormant breast cancer cells in or near microvasculature led 
us to speculate that the vascular endothelial niche might 
play a direct role in the quiescent phenotype of these cells 
via secretion of TSP1 into the tumour microenvironment. 
Our tissue microarray analysis revealed that the stromal 
TSP1 expression is inversely correlated with the 
increased malignancy of invasive ductal carcinoma (IDC) 
with an indication of some survival benefit. In vitro 
experiments further demonstrated that the increased TSP1 
concentration conferred the quiescent phenotypes of IDC 
cells. However, current reports regarding the effects of 
TSP1 on tumour progression are contradictory, with both 
negative and positive roles. For instance, TSP1 has been 
reported to promote progression of many other cancer 
types including glioma [28], melanoma [29], ovarían [30], 
and pancreatic carcinomas [31]. One plausible explanation 
is that TSP1 possesses multiple receptors, therefore, the 
multifaceted effects of TSP1 are due to the varied receptor 
expression profiles. Apparently, the strategy of simply 
direct targeting TSP1 without considering its pleiotropic 
effects for each case may induce severe unwanted side-
effects as well as loss its beneficial functions. TSP1 
contain a high percentage of tryptophan. Tryptophan is the 
rarest essential amino acid in humans, and its levels are 
regulated mainly by the balance between the tryptophan 
absorbance from blood as well as its degradation and 
its use in protein synthesis. Tryptophan degradation 
occurs mostly through the kynurenine pathway, in which 
indoleamine-2,3-dioxygenase (IDO or IDO1) and a splice 
variant of IDO1 known as IDO2 catalyse the oxidation 
of L-tryptophan into kynurenine with reducing the 
availability of tryptophan in the microenvironment and 
cells [32]. Tryptophan deprivation by IDO1 has been 
associated with tumour immune tolerance[33].
Several human cell types have been detected 
to express IDO1, such as activated dendritic cells, 
macrophages, endothelial cells, fibroblasts and multiple 
tumour cells [15, 34, 35]. In agreement with these 
statements, our in vitro experiments revealed that 
endothelial cells co-cultured with malignant breast cancer 
cells or IFNγ highly expressed IDO1. In a tumour tissue 
array, the intensity and area of vascular IDO1 staining 
positively correlated with the stage of breast cancer. 
Furthermore, low vascular IDO1 expression was found to 
have a trend of the superiority of survival. This finding 
will require further confirmation, however, is consistent 
with the clinical studies from the other groups showing 
that IDO1 is gradually up-regulated in a variety of 
cancer patients. High levels of its expression or enzyme 
activity in various cancer types closely associated with 
poor prognostic outcome [36–38]. For instance, IDO1-
expressing colorectal cancer cells are more likely to 
metastasize to distant organs [39]. In breast cancer, high 
IDO1 expression correlated with lymph node involvement 
and with worse recurrence-free survival [23].
In this study, we demonstrate that ECs induced a 
decrease in proliferation of metastatic breast cancer cells 
with cell cycle arrest at the G0/G1 phase. We found that 
IDC cell cycle arrest might be due to quiescence, but no 
senescence. In the context of cellular dormancy, such 
quiescence is a better fit for the cell cycle arrest. Our 
co-culture system also showed that MDA-MB-231 cells 
are capable of inducing IDO1 expression in ECs. The 
conditioned medium from MDA-MB-231 cells showed 
the similar results, but not statistically significant (data 
not shown), which could be due to the lack of spatial and 
temporal parameters, demonstrating that the co-culture 
system adopted in this study is more closer to in vivo 
situations.
Our study confirmed that IFNγ induces the 
expression of IDO1 in ECs. The tumour cell plasticity 
enables the adjustment and changes the adverse 
microenvironment by influencing neighbouring stromal 
cells to involve the secretion of soluble factors. For 
instance, IFNγ has been shown to elevate in the tumour 
stroma [40]. IFNγ was initially identified to play a 
significant role in the detection and elimination of 
tumour cells as well as tumour surveillance by enhancing 
tumour cell immunogenicity [17]. The profound 
immunomodulatory effects of IFNγ has long been 
inspiring clinical applications in antitumour functions. 
However, the clinical development of IFNγ was mostly 
inconclusive due to many of these trials lacking efficacious 
effects of IFNγ. Although IFNγ exhibited antiproliferative, 
antiangiogenic and pro-apoptotic effects on cancer cells, 
there is growing reports of its pro-tumorigenic behaviours 
[41–43]. There are some extreme cases that the IFNγ-
treated patients even fare worse than the untreated 
population [44–46]. Moreover, there are reports of IFNγ 
being pro-tumorigenic even though its inhibiting tumour 
growth was only evident at a much high dose [1].
Taken together, we for the first time provided the 
rationale for the non-canonical role of IFNγ in IDC cells 
evading from tumour dormancy (Figure 6D), other than 
immunomodulation. First, breast cancer cells, in part 
via IFNγ, induce IDO1 expression in endothelial cells, 
leading to tryptophan degradation. Second, the resultant 
reduction in the availability of tryptophan affects TSP1 
synthesis and secretion, which tips between the production 
and degradation of TSP1 in favour of a decrease in TSP1 
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levels in the microenvironment. The deprivation of TSP1 
exerts a permissive role in the breast cancer cells evading 
tumour dormancy. More importantly, our observations 
contribute significantly to our understanding of divergent 
signal-regulation of tumour dormancy as a critical event 
in IDC development and metastasis via crosstalk with 
tumour stroma. Further, these studies raise potential 
concerns regarding the efficacy and safety of IFNγ for the 
cancer treatment. In term of breast cancer, up to 30% of 
those diagnosed as in situ breast cancer exhibit tumour 
dormancy with metastasis-free [7], which will make 
these individuals particularly vulnerable to any adverse 
activities of IFNγ-related breast cancer management.
MATERIALS AND METHODS
Cell culture
A panel of human ECs includes human dermal 
microvascular EC (HEMVEca-D) (Lonza Biologies plc. 
Berkshire, UK), human umbilical vein EC (HUVEC) 
(ICLC, Genova, Italy) and human cerebral microvascular 
EC (CMEC) (Dr Yasuteru Sano, Yamaguchi University 
School of Medicine, Japan). A co-culture system was 
adopted to study the interaction between IDC and 
endothelial cells. ECs were stimulated by three types of 
breast tumour cells. MDA-MB-231 and MDA-MB-436 
are human tumorigenic metastatic breast cancer cell lines, 
MCF-7 is a tumorigenic but non-metastatic breast cancer 
cell line while MCF-10A serves as a non-tumorigenic 
breast epithelial cell, respectively [47]. Brest tumour cells 
were treated with 1 μg/ml CellTrack™ Orange CMRA 
(Life Technologies, Life Technologies, Paisley, UK) in 
a serum-free basal medium at 37°C for 1 minutes. The 
breast cell suspensions added to the top of the HMEVCaD 
cell monolayer. After 48 hours, the co-cultures were 
trypsinized and resuspended in PBS. Breast tumour cells 
and ECs were isolated from the co-cultures through cell 
sorting. We used MoFlo™ XDP (Beckman Coulter (UK) 
Ltd., High Wycombe, UK) for cell sorting by the size and 
labelled fluorescent dyes (Supplementary Figure 2A). We 
tested single cell populations for sequential experiments.
Breast tumour cells were treated with the 
HMEVCa-D cell-conditioned medium, or TSP1 (Sigma-
Aldrich Company Ltd., Dorset, UK) for the indicated 
times. In some experiences, MDA-MB-231 cells were 
also treated with low glucose medium (1 mM glucose). 
25 μM of 1-Methyl-tryptophan (1-MT, Sigma-Aldrich 
Company Ltd., Dorset, UK) was used to treat HMEVCa-D 
cells. At this concentration, 1-MT is not cytotoxic to the 
cells (Supplementary Figure 3D). In some experiments, 
HMEVCa-D cells were subject to treatments of MDA-
MB-231 cell-conditioned medium (normal or low 
glucose), or IFNγ or tryptophan (Sigma-Aldrich Company 
Ltd., Dorset, UK) for the indicated times.
IHC analysis of tissue microarray (TMA)
We purchased a tissue microarray (TMA) slides 
of breast invasive ductal carcinomas (n=100) generated 
by US Biomax Inc. (Rockville, MD, USA). This tissue 
microarray contains forty six cases of invasive duct 
carcinomas, one neuroendocrine carcinoma, three 
medullary carcinomas, forty lymph node metastatic 
carcinomas, ten adjacent normal tissues (single core 
per case) (Figure 3A, 3C). IHC analysis was carried 
out with modified protocol described previously [48]. 
Prior to staining, the slides were dewaxed and hydrated. 
For antigen retrieval, slides were immersed in citrate 
buffer (pH 8.0) and heated in a microwave (≥700W) for 
20 minutes. The slides were quenched with endogenous 
peroxidase by incubation with 3% H2O2 for 5 minutes 
and washed 3 times with TBS. A blocking buffer (1% 
BSA, 1% Marvel and 5% goat serum in TBS) treated 
slides containing serial cores from adjacent tissue 
sections for 1 hour to block any non-specific binding. 
Rabbit anti-TSP1 (1:400) or Rabbit anti-IDO1 (1:200) 
polyclonal antibodies (Abcam, Cambridge, UK) stained 
the slides at 4°C for overnight. We used the antiserum 
against primary antibody as the negative control. 
After primary antibody incubation, the slides were 
washed 3 times in TBS for 5 minutes and incubated 
with secondary antibody for 30 minutes at room 
temperature. The slides were then washed 3 times in 
TBS for 5 minutes each time and incubated with the 
ABC complex for 30 minutes (Vector Laboratories, 
Peterborough, UK). The colour reaction was developed 
with 3,3’-diaminobenzidine (DAB) and the sections 
were then counterstained with haematoxylin (Vector 
Laboratories, Peterborough, UK). Finally, sections 
were washed in tap water, dehydrated through a series 
of graded ethanol, cleared in xylene, and mounted 
in DPX, followed by observation and imaging under 
an optical microscope. At × 200 magnification, the 
staining intensity was assessed in different cell types as 
0 (negative), 1 (weak), 2 (intermediate) and 3 (strong) 
by two observers (FR, LJ).
Histomorphometric analysis of TMA
The area fraction of staining occupied by the tumour 
cells, stroma and vascular ECs was evaluated. We use an 
eyepiece systemic point-sampling grid with 100 points 
and 50 lines to count the number of points overlying 
positively-stained structures at 400× magnification 
(Figure 3E) as previously described [47]. Measurements 
were averaged over five microscopic fields to obtain 
an indexed percentage. Comparisons were performed 
in 20% of the staining by the two observers (LJ, JC), 
the coefficient of variation for the inter-observer error 
regarding cell count was <5%.
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Flow cytometric analysis
MDA-MB-231 cells (single cultured or co-cultured 
with HMEVCa-D cells for 48 hours) were subject to 
assess the proliferative status (Ki67 expression) using 
flow cytometry analysis. MDA-MB-231 cells were 
fixed in 4% formaldehyde for 10 minutes, followed by 
adding ice-cold methanol to gain a final concentration 
of 90% methanol for 30 minutes. The cells were labelled 
with rabbit anti-Ki67 polyclonal antibody conjugated 
with Alexa 488 or rabbit IgG isotype control-Alexa 488 
(Cell Signalling Technology, Inc. MA, USA) at room 
temperature for 1 hour. Flow cytometric analysis was 
using BD FACSCANTO II (Beckman Coulter (UK) Ltd., 
High Wycombe, UK).
We analysed the cell cycle by quantification of 
DNA contents via DNA binding dyes. In S phase, cells 
have more DNA than those in G1 phase. The cells in G2 
are approximately twice as bright as those in G1 phase. 
Breast tumour cells (single culture or co-culture with ECs 
for 48 hours) were fixed in 70% ethanol for 2 hours on 
ice. After PBS wash, 2ug/ml of propidium iodide (PI) was 
added to the cells for 30 minutes at room temperature. We 
performed flow cytometric analysed in BD FACSCANTO 
II (Beckman Coulter (UK) Ltd., High Wycombe, UK). 
The forward scatter (FS) and side scatter (SS) were used 
to select single cell population. The PI histogram plot 
revealed the percentage of cells in each cell cycle phase 
according the manufacturer’s instructions.
Viability assay
A viability assay called crystal violet assay was 
performed as previously described [47]. Briefly, 100μl 
cells were incubated in each well of 96-well plates at 1×105 
cell/ml. The cells were fixed in 4% paraformaldehyde in 
PBS for 15 minutes. After being washing with H2O, the 
plates were stained with 0.1% crystal violet solution for 20 
minutes. The plates were washed with H2O and allowed to 
be air dry, followed by adding 100μl 33% of acetic acid to 
each well. Absorbance of the staining was measured by an 
automatic microtitre plate reader at 590nm.
Quantitative polymerase chain reaction (qPCR) 
assay
Total RNA was extracted from cells using the TRI 
Reagent protocol (Sigma-Aldrich, Dorset, UK). A reverse 
transcription (RT) PCR kit converted 0.5 or 1 μg of RNA 
into complementary DNA according to the manufacturer’s 
instructions (nanoScript 2 Reverse Transcription Kit, primer 
design, Southampton, UK). Polymerase chain reaction 
primers were designed by Primer3 (HIN) as follows: 1) IFNγ 
sense, 5’-TGTCGCCAGCAGCTAAAACA-3’; antisense, 
5’-ACTGAACCTGACCGTACATGCAGGCAGGACAA-
CCATTA-3’; 2) IDO1 sense, 5’-AAAAGGATCCTAATAAG-
CCCC-3’; antisense, 5’-ACTGAACCTGACCGTACA
CAGTCTCCATCACGAAATGA-3’; 3) IDO2 sense, 5’- 
GAGCTGCGGAGCTATCACAT-3’; antisense, 5’- ACTGA
ACCTGACCGTACACCACGTGGGTGAAGGATTGA-3’; 
4) TDO sense, 5’- CCAGGTGCCTTTTCAGTTGC-3’; 
antisense, 5’-ACTGAACCTGACCGTACACTTCGGTA
TCCAGTGTCGGG-3’. The underlined sequence in the 
reverse primers was the additional Z sequence, which is 
complementary to the universal Z probe (TCS Biologicals 
Ltd., Oxford, UK). cDNA was diluted 1:8 and qPCR was 
performed using the Step One Plus RT-PCR mix (Applied 
Biosystems, Life Technologies Ltd, UK).
Western blot analysis
Cells were rinsed with PBS and lysed in ice-
cold lysis buffer containing a cocktail of protease 
inhibitors (Sigma, St. Louis, MO) and phosphatase 
inhibitors (Roche Applied Science, Indianapolis, IN) 
for 30 minutes. After lysates had been centrifuged for 
15 minutes at 15000×g at 4°C, the supernatants were 
collected and their total protein concentrations were 
measured by the MicroBCA reagent (Pierce, Rockford, 
IL). Western blot analysis was performed after sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis 
(equal aliquot of total proteins/lane) and transfer 
onto membranes. The proteins were hybridized with 
primary antibodies and the membranes were incubated 
with horseradish peroxidase (HRP)-conjugated 
secondary antibodies, which were subjected to the 
Amersham ECL system (GE, Trevose, PA) before 
visualizing signals with B:Box Chemi XX6 (Syngene, 
Cambridge, UK).
ELISA analysis
We treated HMEVCa-D cells with MDA-MB-231 
conditioned medium for 48 hours. The medium was 
centrifuged at 200×g for 15 minutes and the supernatant 
was collected for measuring TSP1 concentrations and 
Kynurenine concentrations. Each sample was measured in 
duplicate in each sample using TSP1 ELISA kit (Abcam, 
MA, USA), or L-Kynurenine ELISA kit (Immundiagnostik 
AG, Bensheim, Germany) according to the manufacturers’ 
instructions. The results were expressed as TSP1 (ng/ml) 
and L-Kynurenine (μM), respectively.
IDO1 siRNA knockdowns IDO1 expression in ECs
IDO1 (INDO) ON-TARGET plus SMART-
pool siRNA and ON-TARGET plus siCONTROL was 
purchased from Dharmacon RNA Technologies (Lafayette, 
CO, USA) as the following sequences:
Human INDO (NM_002164), sense, 5′-UCA-
CCAAAUCCACGAUCAUUU-3′, antisense, 5′-PU-
AUGCGAAGAACACUGAAAUU-3′; sense, 5′-UU-
UCAGUGUUCUUCGCAUAUU-3′, antisense, 5′-PUA 
UGCGAAGAACACUGAAAUU-3′; sense, 5′-GUAU 
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GAAGGGUUCU GGGAAUU -3′, antisense, 5′-PUUC 
CCAGAACCCUUCAUACUU-3′; sense, 5′-GAA CGGGA 
CACUUUGCUAAUU-3′, antisense, 5′-PUUAGCAAAG 
UGUCCCGUUCUU-3′.
Log-phase HMVECa-D cells were seeded onto 
6-well plates at the density of 200,000 cells/well. The 
cells were treated with IFNγ (10 ng/mL) and incubated 
at 37°C for 16 hours. 5 μl of siRNA or ON-TARGETplus 
siCONTROL Non-targeting Pool (20μM, Dharmacon) 
was added to 100 μl of serum-free DMEM and mixed. 
The mixture was added with 5 μl of Lipofectamine 2000 
(Thermo Fisher Scientific, Waltham, MA, USA) at room 
temperature for 30 minutes before adding extra 800 μl of 
serum-free DMEM. Then the mixture was added to the 
cells. 1 mL of EGM with endothelial supplements was 
added to each well after 6 hours. Medium was changed 
after 24 hours. After 48 hours, kynurenine content of the 
medium was measured by ELISA. Harvesting of RNA 
extraction was followed by QRT-PCR analysis.
Statistical analysis
We repeated all experiments at least three times. 
The statistical significance for the tissue microarray 
analyses was calculated by ANOVA. Overall survival 
was examined using Kaplan-Meier survival cures with 
Log-rank (Mantel-Cox) test. Also, ANOVA was used 
to calculate the difference among multiple groups of in 
vitro experiments. The significance between in vitro 
experimental and control groups was determined by 
Student’s t-test. The overall difference in IFNγ or IDO1 
expression at the mRNA level using quantitative PCR was 
determined by Wilcoxon-Mann-Whitney analyses. Results 
are expressed as mean±SEM. Statistical analysis was 
performed using GraphPad Prism (version 6; GraphPad 
Software, Inc.) with p<0.05 considered statistically 
significant.
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